{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:12:28Z","timestamp":1786605148198,"version":"build-2736575974"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Industry of the Russian Federation","award":["11411.1008700.13.019"],"award-info":[{"award-number":["11411.1008700.13.019"]}]},{"name":"Ministry of Industry of the Russian Federation","award":["11411.1008700.13.022"],"award-info":[{"award-number":["11411.1008700.13.022"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0176784","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T17:30:51Z","timestamp":1493400651000},"page":"e0176784","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":76,"title":["Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models"],"prefix":"10.1371","volume":"12","author":[{"given":"A. P.","family":"Tkachuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9397-3762","authenticated-orcid":false,"given":"V. A.","family":"Gushchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. D.","family":"Potapov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. V.","family":"Demidenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. G.","family":"Lunin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Gintsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"key":"ref1","first-page":"214","article-title":"Global Tuberculosis Report 2016","year":"2016"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.06.001","article-title":"TB vaccines; promoting rapid and durable protection in the lung","volume":"35","author":"P Andersen","year":"2015","journal-title":"Curr Opin Immunol. Elsevier Ltd"},{"key":"ref3","first-page":"1","article-title":"Global Epidemiology of Tuberculosis","author":"P Glaziou","year":"2015","journal-title":"Cold Spring harb Perspec Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/imr.12270","article-title":"Tuberculosis vaccines: Barriers and prospects on the quest for a transformative tool","volume":"264","author":"CL Karp","year":"2015","journal-title":"Immunol Rev"},{"issue":"8","key":"ref5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrmicro1211","article-title":"The success and failure of BCG\u2014implications for a novel tuberculosis vaccine","volume":"3","author":"P Andersen","year":"2005","journal-title":"Nature reviews Microbiology"},{"key":"ref6","first-page":"1","article-title":"Current status of new tuberculosis vaccine in children","volume":"5515","author":"Y Pang","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","article-title":"Variation in protection by BCG: implications of and for heterologous immunity","volume":"346","author":"PE Fine","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"ref8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S1473-3099(15)00400-4","article-title":"Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: A retrospective population-based cohort study","volume":"16","author":"P. Nguipdop-Djomo","year":"2016","journal-title":"The Lancet Infectious Diseases"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.vaccine.2009.10.114","article-title":"Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen","volume":"28","author":"YAW Skeiky","year":"2010","journal-title":"Vaccine"},{"issue":"9493","key":"ref10","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S0140-6736(05)67145-0","article-title":"Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial","volume":"366","author":"LC Rodrigues","year":"2005","journal-title":"Lancet"},{"key":"ref11","unstructured":"Frick M. The Tuberculosis Vaccines Pipeline: A New Path to the Same Destination? HIV, HCV & TB Pipeline Report (Treatment Action Group). HIV& TB (2015). July 2015. http:\/\/www.pipelinereport.org\/2015\/tb-vaccines<\/ext-link>. Cited 25 August 2016."},{"key":"ref12","article-title":"Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates","author":"EM Agger","year":"2015","journal-title":"Adv Drug Deliv Rev. Elsevier B.V."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.tube.2015.07.001","article-title":"A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents","volume":"95","author":"C Carpenter","year":"2015","journal-title":"Tuberculosis. Elsevier Ltd"},{"key":"ref14","first-page":"1","article-title":"Subunit Vaccine Consisting of Multi-Stage Antigens Has High Protective Efficacy against Mycobacterium tuberculosis Infection in Mice","volume":"8","author":"Q Xin","year":"2013","journal-title":"PLoS One"},{"key":"ref15","first-page":"1","article-title":"Multi-stage tuberculosis subunit vaccine candidate LT69 provides high protection against Mycobacterium tuberculosis infection in mice","volume":"10","author":"H Niu","year":"2015","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.4049\/jimmunol.1102696","article-title":"The importance of adjuvant formulation in the development of a TB vaccine","volume":"188","author":"SL Baldwin","year":"2012","journal-title":"J Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e0155650","DOI":"10.1371\/journal.pone.0155650","article-title":"Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses","volume":"11","author":"AI Tukhvatulin","year":"2016","journal-title":"PLoS One"},{"key":"ref18","first-page":"1","article-title":"Different human vaccine adjuvants promote distinct antigen- independent immunological signatures tailored to different pathogens","author":"NPH Knudsen","year":"2016","journal-title":"Different human vaccine adjuvants promote distinct antigen- independent immunological signatures tailored to different pathogens"},{"key":"ref19","first-page":"1279","article-title":"Nanoengineering of vaccines using natural polysaccharides","volume":"33","author":"AS Cordeiro","year":"2015","journal-title":"Biotechnol Adv. Elsevier B.V."},{"issue":"3","key":"ref20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0264-410X(96)00183-1","article-title":"Adjuvant\u2014a classification and rewiew of their modes of action","volume":"15","author":"J.C. Cox","year":"1997","journal-title":"Vaccine"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s12879-016-1884-5","article-title":"Recombinant domains III of Tick-Borne Encephalitis Virus envelope protein in combination with dextran and CpGs induce immune response and partial protectiveness against TBE virus infection in mice","volume":"16","author":"AS Ershova","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"Suppl 2","key":"ref22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/01.qai.0000446689.08492.a0","article-title":"Problems and prospects of development of the subunit TB vaccine","volume":"65","author":"A. Tkachuk","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1083\/jcb.200611141","article-title":"Error bars in experimental biology","volume":"177","author":"G Cumming","year":"2007","journal-title":"J Cell Biol"},{"key":"ref24","first-page":"2773","article-title":"Protection of Mice with a Tuberculosis Subunit Vaccine Based on a Fusion Protein of Antigen 85B and ESAT-6","volume":"69","author":"AW Olsen","year":"2001","journal-title":"Microbiology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1016\/j.vaccine.2006.03.072","article-title":"Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31","volume":"24","author":"EM Agger","year":"2006","journal-title":"Vaccine"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0114602","article-title":"Safety and immunogenicity of h1\/ic31h, an adjuvanted tb subunit vaccine, in hiv-infected adults with cd4+ lymphocyte counts greater than 350 cells\/mm3: A phase ii, multi-centre, double-blind, randomized, placebo-controlled trial e114602","volume":"9","author":"K Reither","year":"2014","journal-title":"PLoS One"},{"key":"ref27","first-page":"3592","article-title":"The tuberculosis vaccine H4: IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial","volume":"33","author":"H Geldenhuys","year":"2015","journal-title":"Vaccine. Elsevier Ltd"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm.2285","article-title":"A multistage tuberculosis vaccine that confers efficient protection before and after exposure","volume":"17","author":"C Aagaard","year":"2011","journal-title":"Nat Med. Nature Publishing Group"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039909","article-title":"The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity","volume":"7","author":"R Billeskov","year":"2012","journal-title":"PLoS One"},{"key":"ref30","article-title":"Subunit vaccine H56\/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung","author":"JS Woodworth","year":"2016","journal-title":"Mucosal Immunol. Nature Publishing Group"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.3892\/mmr.2015.3770","article-title":"Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice","volume":"12","author":"W Li","year":"2015","journal-title":"Mol Med Rep"},{"key":"ref32","first-page":"1","article-title":"Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis","author":"YY Chen","year":"2014","journal-title":"J Microbiol Immunol Infect. Elsevier Taiwan LLC"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ebiom.2016.04.010","article-title":"Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-na\u00efve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial","volume":"7","author":"DF Hoft","year":"2016","journal-title":"EBioMedicine. The Authors"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: A systematic review of randomized controlled trials","volume":"58","author":"P Mangtani","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref35","first-page":"1","article-title":"Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Gue rin vaccination against tuberculosis","volume":"17","author":"I Abubakar","year":"2013","journal-title":"Health Technol Assess (Rockv)"},{"key":"ref36","first-page":"2086","article-title":"Long-term Efficacy of BCG Vaccine","volume":"291","author":"NE Aronson","year":"2004","journal-title":"Long-term Efficacy of BCG Vaccine"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ebiom.2016.04.010","article-title":"Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-na\u00efve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial","volume":"7","author":"DF Hoft","year":"2016","journal-title":"EBioMedicine. The Authors"},{"key":"ref38","first-page":"1","article-title":"TLR9 mediates S. aureus killing inside osteoblasts via induction of oxidative stress","author":"W Mohamed","year":"2016","journal-title":"BMC Microbiol. BMC Microbiology"},{"key":"ref39","first-page":"371","article-title":"Targeting the C-type Lectins-Mediated Host-Pathogen Interactions with Dextran","volume":"17","author":"S Pustylnikov","year":"2014","journal-title":"Targeting the C-type Lectins-Mediated Host-Pathogen Interactions with Dextran"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"MD Tameris","year":"2013","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"p469","DOI":"10.1038\/503469e","article-title":"TB vaccine failure was predictable","volume":"503","author":"P Beverley","year":"2013","journal-title":"Nature"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","article-title":"Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers","volume":"28","author":"JT van Dissel","year":"2010","journal-title":"Vaccine"},{"key":"ref43","first-page":"2100","article-title":"Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection","volume":"29","author":"JT van Dissel","year":"2011","journal-title":"Vaccine. Elsevier Ltd"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1164\/rccm.200811-1704OC","article-title":"Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing","volume":"180","author":"RN Van Zyl-Smit","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"ref45","first-page":"143","article-title":"The Tuberculosis Prevention Pipeline","author":"B. M Frick","year":"2016","journal-title":"The Tuberculosis Prevention Pipeline"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.1073\/pnas.1015153108","article-title":"Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection","volume":"108","author":"KA Millington","year":"2011","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0176784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T18:52:03Z","timestamp":1588963923000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0176784"}},"subtitle":[],"editor":[{"given":"Pere-Joan","family":"Cardona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,4,28]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0176784","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,28]]}}}